Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.18 USD | +0.29% | +1.80% | -10.82% |
Apr. 30 | Kenvue's Q1 Challenges Prompt Investor Caution; Visibility May Alter Sentiment, UBS Says | MT |
Apr. 22 | Contaminated cough syrup in Africa no longer available - WHO | RE |
Evolution of the average Target Price on Kenvue Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Kenvue Inc.
Bernstein | |
William Blair & Co. | |
Goldman Sachs | |
UBS | |
Deutsche Bank Securities | |
RBC Capital Markets | |
Piper Sandler | |
JPMorgan Chase | |
Canaccord Genuity | |
Argus | |
Edward Jones | |
Citigroup | |
HSBC | |
BofA Securities | |
BNP Paribas Exane |
EPS Revisions
- Stock Market
- Equities
- KVUE Stock
- Consensus Kenvue Inc.